RehaBEElitation - Serious Game-Based Experimental Protocol to Improve Manual Dexterity in Individuals With Parkinson's Disease
NCT07928050, Not applicable, Completed, Federal University of Uberlandia
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | RehaBEElitation - Serious Game-Based Experimental Protocol to Improve Manual Dexterity in Individuals With Parkinson's Disease | ClinicalTrials.gov |
| NCT number | NCT07928050 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 27 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Federal University of Uberlandia | ClinicalTrials.gov |
| Conditions | Parkinson Disease | ClinicalTrials.gov |
| Interventions | RehaBEElitation serious game, Home exercise booklet | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Box and Block Test | Baseline and 6 weeks | Number of blocks transferred in 60 seconds with the most affected hand. Higher scores mean a better outcome. | ClinicalTrials.gov |
| Primary | Nine-Hole Peg Test | Baseline and 6 weeks | Time in seconds to place and remove nine pegs. Higher values mean a worse outcome. | ClinicalTrials.gov |
| Primary | MDS-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) | Baseline and 6 weeks | Clinical scale of motor signs. Each item is rated from 0 (normal) to 4 (severe); higher scores mean a worse outcome. | ClinicalTrials.gov |
| Primary | Parkinson's Disease Questionnaire (PDQ-39) | Baseline and 6 weeks | Disease-specific quality of life. Summary index from 0 to 100; higher scores mean a worse outcome. | ClinicalTrials.gov |
| Primary | International Classification of Functioning, Disability and Health (ICF) checklist | Baseline and 6 weeks | Activity and participation components; functioning and disability in daily life. | ClinicalTrials.gov |
| Primary | Muscle activation of the flexor carpi radialis (surface electromyography) | Baseline and 6 weeks | EMG of the flexor carpi radialis, normalised to the maximal voluntary contraction (%MVC), averaged across the reaching task, the Box and Block Test, the Nine-Hole Peg Test and the Trail Making Test. | ClinicalTrials.gov |
| Primary | Muscle activation of the extensor carpi ulnaris (surface electromyography) | Baseline and 6 weeks | EMG of the extensor carpi ulnaris, normalised to the maximal voluntary contraction (%MVC), averaged across the reaching task, the Box and Block Test, the Nine-Hole Peg Test and the Trail Making Test. | ClinicalTrials.gov |
| Primary | Muscle activation of the biceps brachii (surface electromyography) | Baseline and 6 weeks | EMG of the biceps brachii, normalised to the maximal voluntary contraction (%MVC), averaged across the reaching task, the Box and Block Test, the Nine-Hole Peg Test and the Trail Making Test. | ClinicalTrials.gov |
| Primary | Muscle activation of the triceps brachii (surface electromyography) | Baseline and 6 weeks | EMG of the triceps brachii, normalised to the maximal voluntary contraction (%MVC), averaged across the reaching task, the Box and Block Test, the Nine-Hole Peg Test and the Trail Making Test. | ClinicalTrials.gov |
| Primary | Muscle activation of the anterior deltoid (surface electromyography) | Baseline and 6 weeks | EMG of the anterior deltoid, normalised to the maximal voluntary contraction (%MVC), averaged across the reaching task, the Box and Block Test, the Nine-Hole Peg Test and the Trail Making Test. | ClinicalTrials.gov |
| Primary | Trail Making Test part A | Baseline and 6 weeks | Time in seconds to complete part A. Higher values mean a worse outcome. | ClinicalTrials.gov |
| Primary | Trail Making Test part B | Baseline and 6 weeks | Time in seconds to complete part B. Higher values mean a worse outcome. | ClinicalTrials.gov |
| Primary | Handwriting movement analysis | Baseline and 6 weeks | Spiral and sinusoid drawings (10 copies of each). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 37346638 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)